Identifying the FMRP regulated mRNAs or proteins as causal factors for hypocholesterolemia could have implications not only for identifying potential FXS biomarkers but also in finding novel PCSK9 inhibitors for the treatment of hypercholesterolemia. This evidence concerns the gene FMR1 and fragile X syndrome.